MetaVia Inc.
MTVA
Classifica tra le azioni
#32908
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Prezzo delle azioni
$1.28
Capitalizzazione di mercato
$8.43M
Variazione (1 giorno)
4.07%
Variazione (1 anno)
-21.47%
Paese
US
Scambia MetaVia Inc. (MTVA)
Categoria
Healthcare
Cronologia dei frazionamenti azionari per MetaVia Inc. (MTVA)
L’azione MetaVia Inc. (simbolo: MTVA) ha subito un totale di 3 frazionamenti.
L’ultimo frazionamento è avvenuto il Dec 21, 2023.
Una quota di MTVA acquistata prima di Dec 31, 2019 equivale oggi a 0.00016666666666667 quote di MTVA.
L’ultimo frazionamento è avvenuto il Dec 21, 2023.
Una quota di MTVA acquistata prima di Dec 31, 2019 equivale oggi a 0.00016666666666667 quote di MTVA.
Elenco dei frazionamenti azionari
| Anno | Frazionamento | Moltiplicatore | Moltiplicatore cumulativo |
|---|---|---|---|
| 2023-12-21 | 1:8 | x0.125 | x0.00016666666666667 |
| 2022-09-13 | 1:30 | x0.033333333333333 | x0.0013333333333333 |
| 2019-12-31 | 1:25 | x0.04 | x0.04 |
Frazionamenti azionari di aziende simili o concorrenti
| Azienda | Numero di frazionamenti azionari | Moltiplicatore cumulativo | Il paese |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
